These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 17705809

  • 1. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat.
    Nurmio M, Toppari J, Zaman F, Andersson AM, Paranko J, Söder O, Jahnukainen K.
    Int J Androl; 2007 Aug; 30(4):366-76; discussion 376. PubMed ID: 17705809
    [Abstract] [Full Text] [Related]

  • 2. Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis.
    Nurmio M, Kallio J, Toppari J, Jahnukainen K.
    Reprod Toxicol; 2008 Aug; 25(4):442-6. PubMed ID: 18472395
    [Abstract] [Full Text] [Related]

  • 3. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.
    Cancer Res; 2005 Mar 01; 65(5):1897-903. PubMed ID: 15753388
    [Abstract] [Full Text] [Related]

  • 4. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
    Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, Egorin MJ, Tahan SR, Dezube BJ.
    J Clin Oncol; 2005 Feb 10; 23(5):982-9. PubMed ID: 15572730
    [Abstract] [Full Text] [Related]

  • 5. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571.
    Yoshitani K, Honoki K, Morishita T, Kido A, Miyauchi Y, Mii Y, Takakura Y.
    In Vivo; 2003 Feb 10; 17(3):255-8. PubMed ID: 12929576
    [Abstract] [Full Text] [Related]

  • 6. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
    Knight LA, Di Nicolantonio F, Whitehouse PA, Mercer SJ, Sharma S, Glaysher S, Hungerford JL, Hurren J, Lamont A, Cree IA.
    Anticancer Drugs; 2006 Jul 10; 17(6):649-55. PubMed ID: 16917210
    [Abstract] [Full Text] [Related]

  • 7. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG.
    J Cutan Pathol; 2006 Apr 10; 33(4):280-5. PubMed ID: 16630177
    [Abstract] [Full Text] [Related]

  • 8. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH.
    Gynecol Oncol; 2004 Oct 10; 95(1):32-6. PubMed ID: 15385107
    [Abstract] [Full Text] [Related]

  • 9. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
    Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM.
    Cancer; 2003 Aug 15; 98(4):758-64. PubMed ID: 12910520
    [Abstract] [Full Text] [Related]

  • 10. [Imatinib].
    Urabe A.
    Gan To Kagaku Ryoho; 2003 Aug 15; 30(8):1191-6. PubMed ID: 12938280
    [Abstract] [Full Text] [Related]

  • 11. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
    Ren H, Tan X, Dong Y, Giese A, Chou TC, Rainov N, Yang B.
    Basic Clin Pharmacol Toxicol; 2009 Mar 15; 104(3):241-52. PubMed ID: 19159435
    [Abstract] [Full Text] [Related]

  • 12. [Imatinib and solid tumours].
    Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, Ranchère D, Decouvelaere AV, Alberti L, Tabone-Eglinger S, Blay JY, Cassier P.
    Bull Cancer; 2008 Jan 15; 95(1):99-106. PubMed ID: 18230575
    [Abstract] [Full Text] [Related]

  • 13. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy.
    Savikko J, Taskinen E, Von Willebrand E.
    Transplantation; 2003 Apr 27; 75(8):1147-53. PubMed ID: 12717194
    [Abstract] [Full Text] [Related]

  • 14. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.
    Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, Slavin S, Israel Glivec in Solid Tumors Study Group.
    Endocr Relat Cancer; 2006 Jun 27; 13(2):535-40. PubMed ID: 16728580
    [Abstract] [Full Text] [Related]

  • 15. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo.
    Hacker TA, Griffin MO, Guttormsen B, Stoker S, Wolff MR.
    J Invasive Cardiol; 2007 Jun 27; 19(6):269-74. PubMed ID: 17541129
    [Abstract] [Full Text] [Related]

  • 16. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
    Mukherjee J, Kamnasaran D, Balasubramaniam A, Radovanovic I, Zadeh G, Kiehl TR, Guha A.
    Cancer Res; 2009 Jun 15; 69(12):5099-107. PubMed ID: 19509233
    [Abstract] [Full Text] [Related]

  • 17. Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits.
    Leppänen O, Rutanen J, Hiltunen MO, Rissanen TT, Turunen MP, Sjöblom T, Brüggen J, Bäckström G, Carlsson M, Buchdunger E, Bergqvist D, Alitalo K, Heldin CH, Ostman A, Ylä-Herttuala S.
    Circulation; 2004 Mar 09; 109(9):1140-6. PubMed ID: 14769706
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.
    Leuk Res; 2008 Dec 09; 32(12):1830-6. PubMed ID: 18571721
    [Abstract] [Full Text] [Related]

  • 19. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A, Zoltan-Jones A, Strizzi L, Bargo S, Kimura K, Salomon D, Callahan R.
    Oncogene; 2007 Feb 01; 26(5):662-72. PubMed ID: 16878155
    [Abstract] [Full Text] [Related]

  • 20. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
    Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA, Dörken B, le Coutre P.
    Blood Cells Mol Dis; 2005 Feb 01; 34(2):181-5. PubMed ID: 15727903
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.